Sunday, November 28, 2021
Home Health Bharat Biotech update the efficacy of Covaxin to 65.2% against the Delta...

Bharat Biotech update the efficacy of Covaxin to 65.2% against the Delta variant – ET HealthWorld


Commending the investigators from AIIMS on the BBV152 study published in Lancet Infectious Diseases, Bharat Biotech stated that these results provide evidence for effectiveness for COVAXIN in real life settings. Updated the efficacy of Covaxin to 65.2 percnt against the Delta variant in – Effectiveness Study on Delta Variant – Lancet Infectious Diseases, published on Tuesday.

“An effectiveness result of 50% achieved during the peak COVID-19 delta variant wave in India, in a high risk study population of physicians and healthcare workers, in a hospital environment, and who are challenged repeatedly with high viral loads, provides insights into the efficacy and effectiveness of Covaxin,” the company said in a statement

“These results compare well with the 65.2% efficacy against the delta variant obtained during the controlled phase III clinical trials of Covaxin conducted among the general population. This study also shows that Covaxin meets the WHO efficacy criteria for COVID-19 vaccines for the dreaded Delta variants,” the statement added.

The study, titled “Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study” assessed 2,714 hospital workers at AIIMS in Delhi, from April 15–May 15, who were symptomatic and underwent RT-PCR test for COVID-19 detection. The results were published in The Lancet Infectious Diseases Journal.

Results of an interim study conducted by AIIMS has shown that two doses of Covaxin, the indigenous vaccine developed by Indian Council of Medical Research (ICMR) in collaboration with Bharat Biotech, is 50% effective in preventing symptomatic infection due to COVID-19. This is lower than the 77.8 percent efficacy claimed by Bharat Biotech after phase 3 trials of the vaccine.

Covaxin, also known as BBV152, a two-dose regimen, with a gap of 28 days between each dose developed in collaboration with the Indian Council of Medical Research (ICMR) one of the two most widely-used vaccines in the national inoculation exercise. On November 3, it was granted Emergency Use Listing (EUL) by the World Health Organization (WHO).





Source link

RELATED ARTICLES

‘Be vigilant’, WHO tells Southeast Asia countries amid case surge, emergence of new variant – ET HealthWorld

Amid the detection of a new coronavirus variant and surge in cases elsewhere, the WHO Saturday asked countries in the southeast Asia region...

Need to be proactive in light of the new variant: PM – ET HealthWorld

New Delhi : Urging people to be proactive in light of the new variant B.1.1.529 -Omicron of COVID 19, Prime Minister Narendra Modi...

Is use of aspirin linked with increased risk of heart failure?

According to a new research, taking aspirin is associated with a 26 per cent increased risk of heart failure. The other factors associated...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -stock market course

Most Popular

No need to panic over new Covid-19 variant: ICMR | India News – Times of India

NEW DELHI: Amid mounting concern over cases of the new variant of concern Omicron detected in some countries, the Indian Council of Medical...

Weekly Tarot Card Readings: Tarot prediction for November 28-December 04

ARIES (March 21-April 20)Love: The StrengthMood: The HangedCareer: The EmpressThere are strong possibilities that your efforts to improve your professional standards may bear...

UK, Germany, Italy Detect Cases Of New Covid Variant

<!-- -->New Covid strain: Several nations have imposed restrictions on travel from southern Africa. (File)London/Berlin/Amsterdam: Britain, Germany and Italy detected cases of the...

Recent Comments

%d bloggers like this: